OTC Prilosec
Executive Summary
Procter & Gamble hopes to receive approval for Rx-to-OTC switch of AstraZeneca's proton pump inhibitor Prilosec (omeprazole) "before the end of this next fiscal year," which ends June 30, 2002, P&G CEO A.G. Lafley tells analysts during June 15 teleconference. P&G has marketing rights for OTC Prilosec. In October, FDA's Nonprescription and Gastrointestinal Drugs Advisory Committees voted that the switch NDA was not approvable (1"The Pink Sheet" Oct. 23, 2000, p. 24)